Anti-VEGF blockage was shown to have a potential to suppress the progression of mesothelioma cells, and first-line combination therapy of bevacizumab with cisplatin and pemetrexed led to prolonged OS compared to the same chemotherapy alone (10, 13). This evidence concerns the gene VEGFA and mesothelioma.